Alembic Pharma Receives USFDA Approval for Heart Disease Drug
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ticagrelor Tablets, 60 mg.
The company announced the approval, marking a significant development in the pharmaceutical field.
No specific quote available.
Ruchika Sharma, Correspondent for the Business Section, reported on the update.
Alembic Pharma: received USFDA approval for heart disease drug.
- Company: Alembic Pharmaceuticals Limited
- Approval: US Food & Drug Administration (USFDA)
- Drug: Ticagrelor Tablets, 60 mg
Author summary: Alembic Pharma gets USFDA nod for heart disease drug.
More News
- An Obscure Military Program Helps Local Cops Buy Armored Cars and Spyware. It Might Balloon Under Trump.
- How Discrimination and Stress Impact the Mental Health of Young Sexual Minority Men
- Pashinyan Confident Armenians Will Support Peace Process in 2026 Parliamentary Election
- Most Exciting Prospects for 2026: AL Central
- Uzbekistan pitches worldwide initiatives at UNESCO General Conference
- Prime Minister Pashinyan should be excommunicated and arrested
- Israeli Colonizers Invade Bedouin Village Near Jerusalem
- CDEDI urges MPs to prioritize citizens’ interests new parliamentary term Malawi 24 | Latest News from Malawi
- Pashinyan's election campaign could lead to a split in Armenian society
- The Tech Symphony: AI's Crescendo and the Gadget Orchestra